UC Berkeley's Nurix Therapeutics will use the capital to prepare two protein modulation-based immuno-oncology drugs for the clinic.

Nurix Therapeutics, a US-based cancer drug developer spun out of University of California (UC), Berkeley, has completed a $120m round led by life sciences investment firm Foresite Capital. Incubator and venture firm Third Rock Ventures also contributed to the round, as did Bain Capital’s Life Sciences unit, Tavistock Group’s Boxer Capital, EcoR1 Capital, Redmile Group,…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.